Chlorambucil-induced myoclonus in a cat with lymphoma

Journal of the American Animal Hospital Association

Volumn 39, Issue 3, 2003, Pages 283-287

  Benitah, Noémi ^a,c   de Lorimier, Louis Philippe ^a   Gaspar, Michele ^b   Kitchell, Barbara E ^a  

^a Veterinary Teaching Hospital   (United States)

^b Cat Clinic   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ATROPINE; CEFAZOLIN; CHLORAMBUCIL; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYPROHEPTADINE; DIAZEPAM; FAMOTIDINE; METALDEHYDE; METRONIDAZOLE; POTASSIUM CHLORIDE; PREDNISONE; PREDNISONE ACETATE; RANITIDINE; TYLOSIN; VINCRISTINE; VITAMIN B COMPLEX;

AGITATION; ANIMAL DISEASE; ARTICLE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG INDUCED DISEASE; DRUG MEGADOSE; EXPERIMENTAL ANIMAL; INTESTINE LYMPHOMA; MALE; MUSCLE TWITCH; MYOCLONUS SEIZURE; NEUROTOXICITY; NONHUMAN; TONIC CLONIC SEIZURE; TREMOR;

ANIMALIA; FELIS CATUS;

EID: 0038627982     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/0390283     Document Type: Article

References (42)

1. Fondacaro JV, Richter KP, Carpenter JL, Hart JR, Hill SL, Fettman MJ. Feline gastrointestinal lymphoma: 67 cases (1988-1996). Eur J Comp Gastroenterol 1999;4:5-11.
2. Colvin OM. Antitumor alkylating agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:363-376.
3. Dalhiwal R, Kitchell BE. CVT update: anticancer drugs and protocols using traditional drugs. In: Bonagura JD, ed. Kirk's current veterinary therapy XIII. Philadelphia: WB Saunders, 2000:465-473.
4. Kitchell BE, LaRue SM, Rooks RL. Veterinary cancer therapy handbook. 2nd ed. Lakewood, Colorado: AAHA Press, 2000:1.1-2.7.
5. Chun R, Garrett L, MacEwen EG. Cancer chemotherapy. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders, 2001:98-103.
6. Mahony OM, Moore AS, Cotter SM, Engler SJ, Brown D, Penninck DG. Alimentary lymphoma in cats: 28 cases (1988-1993). J Am Vet Med Assoc 1995;207:1593-1598.
7. Frazier DL, Hahn KA. Commonly used drugs. In: Hahn KA, Richardson RC, eds. Cancer chemotherapy, a veterinary handbook. Malvern, Pennsylvania: Williams and Wilkins, 1995:90.
8. Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
9. Hohenhaus A. Syndromes of hyperglobulinemia. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders, 1995:523-530.
10. Moore A, Mahony OM. Treatment of feline malignant lymphoma. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders, 1995:498-502.
11. Helton-Rhodes KA. Feline immunomodulators. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders, 1995:581-584.
12. White SD. Nonsteroidal immunosuppressive therapy. In: Bonagura JD, ed. Kirk's current veterinary therapy XIII. Philadelphia: WB Saunders, 2001:536-538.
13. Ruiz de Gopegui R, Feldman BF. Erythrocyte diseases. In: Leib S, Monroe WE, eds. Practical small animal medicine. Philadelphia: WB Saunders, 1995:931-945.
14. Miller E. The use of cytotoxic agents in the treatment of immunemediated diseases of dogs and cats. Sem Vet Med Surg (Sm Anim) 1997;12(3):157-160.
15. Salloum E, Khan KK, Cooper DL. Chlorambucil-induced seizures. Cancer 1997;79(5):1009-1013.
16. Wolfson S, Olney MB. Accidental ingestion of a toxic dose of chlorambucil. J Am Med Assoc 1957;165:239-240.
17. Hagan EC, Hurwitz L, Davis KJ, Jenner PM. Toxic effects of chlorambucil (CB 1348) in laboratory animals. Fed Proc 1957;16:304.
18. Pradhan SN, Marsan CA. Chlorambucil toxicity and EEG "centrencephalic" patterns. Epilepsia 1963;4:1-14.
19. Testa G, Semerano A, Lion P. [Aspects of centroencephalic epilepsy reproduced in the rabbit by administration of chlorambucil]. Boll Suc Ital Biol Sper 1968;44(14):1121-1124.
20. Lion P, Testa G, Semerano A. Periodic myoclonic epilepsy in the kitten: an experimental study on the reactivity of the immature brain. Electroencephalogr Clin Neurophysiol 1970;28(2):213.
21. Palestini M, Meglio M, Cavazza B, Sannita W, Rossi GF. Studio sperimentale delle proprieta convulsivanti del "chlorambucil." Soc Ital EEG Neurofisiol Clin 1971:262-269.
22. Palestini M, Meglio M, Rossi GF. [A model of experimental epilepsy (chlorambucil)]. Rev Med Chil 1972;100(10):1189-1195.
23. Product information: leukeran (chlorambucil). Revised August 2001, GlaxoSmithKline, North Carolina.
24. Byrne TN, Moseley TA, Finer MA. Myoclonic seizures following chlorambucil overdose. Ann Neurol 1981;9(2):191-194.
25. Vandenberg SA, Kulig K, Spoerke DG, Hall AH, Bailie VJ, Rumack BH. Chlorambucil overdose: accidental ingestion of an antineoplastic drug. J Emerg Med 1988;6(6):495-498.
26. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978;93(3):516-518.
27. Naysmith A, Robson RH. Focal fits during chlorambucil therapy. Postgrad Med J 1979;55(649):806-807.
28. Ammenti A, Reitter B, Muller-Wiefel DE. Chlorambucil neurotoxicity: report of two cases. Helv Paediatr Acta 1980;35(3):281-287.
29. Ichida F, Konishi T, Asada R, et al. Chlorambucil central nervous toxicity: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. Eur J Pediatr 1985;144(3):283-286.
30. LaDelfa I, Bayer N, Myers R, Hoffstein V. Chlorambucil-induced myoclonic seizures in an adult. J Clin Oncol 1985;3(12):1691-1692.
31. Ciobanu N, Runowicz C, Gucalp R, et al. Reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for ovarian carcinoma. Cancer Treat Rep 1987;71(12):1324-1325.
32. Blumenreich MS, Woodcock TM, Sherrill EJ, et al. A phase I trial of chlorambucil administered in short pulses in patients with advanced malignancies. Cancer Invest 1988;6(4):371-375.
33. Bailey RR. Remission induced by chlorambucil in steroid-responsive, frequently relapsing nephrotic syndrome that relapsed after cyclophosphamide. N Z Med J 1989;102(872):379-381.
34. Wyllie AR, Bayliff CD, Kovacs MJ. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother 1997;31(2):171-174.
35. Apaydin S, Ozaras R, Erek E, et al. Chlorambucil-induced seizure in a patient with nephrotic syndrome. Nephron 1999;82(4):368.
36. Jourdan E, Topart D, Pinzani V, Joudan J. Chlorambucil/prednisone-induced seizures in a patient with non-Hodgkin's lymphoma. Am J Hematol 2001;67(2):147.
37. Martin M, Diz-Rubio E, Casado A, et al. Prednimustine-induced myoclonus: a report of three cases. Acta Oncol 1994;33(1):81-82.
38. Monnerat C, Gander M, Leyvraz S. A rare case of prednimustine-induced myoclonus. J Natl Cancer Inst 1997;89(2):173-174.
39. Beinert T, Masuhr F, Mwela E, et al. Neuropathy under chemotherapy. Eur J Med Res 2000;5(10):415-423.
40. Weiss RB. Miscellaneous toxicities. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:2964-2972.
41. Kisseberth WC, MacEwen EG. Complications of cancer and its treatment. In: Withrow S, MacEwen EG, eds. Small animal clinical oncology. Philadelphia: WB Saunders, 2001:211.
42. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977;21(3):247-254.